Skip to content
Study details
Enrolling now

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

Canadian Cancer Trials Group
NCT IDNCT06235697ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

710

Study length

about 9 years

Ages

18+

Sex

Male only

Locations

46 sites in CA, IL, MO +4

What this study is about

This trial is testing whether a new way of giving radiation therapy, called SBRT, is as effective as usual radiation therapy for prostate cancer. The treatment involves suppressing testosterone levels with medication (ADT) along with radiation therapy and brachytherapy.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Radiation
  • 2.Receive Radiation SBRT only
  • 3.Take ADT

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
Randomized (Open Label)

You are randomly assigned, but you will know your treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

hormone therapy

Endpoints

Primary: To compare the progression-free survival (PFS) of SBRT versus conventional EBRT plus brachytherapy boost defined as time to biochemical failure, initiation of salvage therapy, local-regional recurrence, distant progression, or death

Secondary: Economic Outcomes using EQ-5D-5L, Economic Outcomes using FACIT-COST, Overall Survival analysed using a Cox proportional hazards model and graphically described using the Kaplan-Meier method, Participant-reported tolerability using PRO-CTCAE questionnaire, Safety and tolerability assessed by CTCAE v5.0

Procedures

radiation

Body systems

Oncology